OLIG2 and neoplasm: We classified sPNET patients into three molecular subgroups based on differential expression of tumor cell lineage markers LIN28 and OLIG2 according to the methods of Picard et al.[11] Two patients (7%) belonged to Group 1, 7 patients (24%) belonged to Group 2, and 20 patients (69%) belonged to Group 3.